



Eurofins subsidiary agrees to acquire a further 7% additional stake in Cerep S.A.

2 January 2013

Eurofins Scientific (EUFI.PA) and the Fondation de l'Institut Pasteur de Lille (IPL Foundation), have agreed on the acquisition of a block of 865,100 shares in Cerep S.A. belonging to the Foundation by a Eurofins subsidiary, subject to the fulfilment of conditions precedent.

The shares represent 6.86% of the total capital of Cerep, bringing the total stake that Eurofins has agreed to acquire to 15.34%, following its acquisition of CEO and founder Mr. Thierry Jean's 8.48% stake announced on 21 December 2012¹.

The agreed price of EUR 2 per share is equal to the price to be paid for Mr. Thierry Jean's stake, and the price referred to in the draft joint notice relating to Eurofins' tender offer for the remainder of Cerep's capital as submitted to the Autorité des Marchés Financiers (AMF), also on 21 December 2012. As announced previously, pending a conformity decision from the AMF, the tender offer, which is still under the AMF's review, proposes a purchase price of EUR 2 per share to existing Cerep shareholders, equal to the price to be paid for Mr. Jean's stake, and the price agreed with the IPL Foundation.

This transaction would reinforce the presence of Eurofins in the discovery pharmacology market following its acquisition of Pan Labs in the US in September 2012. If the tie-up were to be confirmed, Mr. Thierry Jean, Cerep CEO, would further develop the business in close partnership with Eurofins.

¹ Eurofins Press Release dated 21 December 2012 (<http://www.eurofins.com/en/media-centre/press-releases/2012-12-21.aspx>).

For further information please contact:

Investor Relations
Phone: +32-2-766-1620
E-mail: ir@eurofins.com

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agrosience, genomics and central laboratory services.

With over 12,500 staff in more than 170 laboratories across 33 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological

substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters ERF, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.